Platelet-Rich Plasma Injections: Pharmacological and Clinical Considerations in Pain Management
Purpose of Review Regenerative medicine through interventional pain procedures is evolving with data demonstrating efficacy for a number of pain states in recent years. Platelet-rich plasma (PRP), defined as a sample of plasma with a platelet concentration 3 to 5 times greater than the physiologic platelet concentration found in healthy whole blood, releases bioactive proteins which can restore anatomical function in degenerative states. PRP is dense in growth factors, such as platelet-derived growth factor, transforming growth factor-beta1, basic fibroblastic growth factor, vascular endothelial growth factor, and epidermal growth factors. Recent Findings To date, well-designed case–control or cohort studies for the use of PRP have demonstrated efficacy in lumbar facet joint, lumbar epidural, and sacroiliac joint injections. At present, there is only level IV evidence indicating the need for larger and more carefully controlled prospective studies. PRP is utilized autogenously in order to facilitate healing and injection and has been studied in the long-term management of discogenic low back pain. In this regard, numerous studies have evaluated PRP to steroid injections in chronic pain states with favorable results. Summary PRP represents an opportunity for a new strategy in the therapeutic treatment of degenerative states of spines, joints, and other locations throughout the body with evolving data demonstrating both safety and long-term efficacy..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Current pain and headache reports - 26(2022), 10 vom: 10. Sept., Seite 741-749 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Grossen, Audrey A. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Chronic pain |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s11916-022-01082-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2079822098 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2079822098 | ||
| 003 | DE-627 | ||
| 005 | 20230518155842.0 | ||
| 007 | tu | ||
| 008 | 230131s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11916-022-01082-2 |2 doi | |
| 035 | |a (DE-627)OLC2079822098 | ||
| 035 | |a (DE-He213)s11916-022-01082-2-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Grossen, Audrey A. |e verfasserin |0 (orcid)0000-0003-1321-0245 |4 aut | |
| 245 | 1 | 0 | |a Platelet-Rich Plasma Injections: Pharmacological and Clinical Considerations in Pain Management |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Purpose of Review Regenerative medicine through interventional pain procedures is evolving with data demonstrating efficacy for a number of pain states in recent years. Platelet-rich plasma (PRP), defined as a sample of plasma with a platelet concentration 3 to 5 times greater than the physiologic platelet concentration found in healthy whole blood, releases bioactive proteins which can restore anatomical function in degenerative states. PRP is dense in growth factors, such as platelet-derived growth factor, transforming growth factor-beta1, basic fibroblastic growth factor, vascular endothelial growth factor, and epidermal growth factors. Recent Findings To date, well-designed case–control or cohort studies for the use of PRP have demonstrated efficacy in lumbar facet joint, lumbar epidural, and sacroiliac joint injections. At present, there is only level IV evidence indicating the need for larger and more carefully controlled prospective studies. PRP is utilized autogenously in order to facilitate healing and injection and has been studied in the long-term management of discogenic low back pain. In this regard, numerous studies have evaluated PRP to steroid injections in chronic pain states with favorable results. Summary PRP represents an opportunity for a new strategy in the therapeutic treatment of degenerative states of spines, joints, and other locations throughout the body with evolving data demonstrating both safety and long-term efficacy. | ||
| 650 | 4 | |a Platelet-rich plasma | |
| 650 | 4 | |a Chronic pain | |
| 650 | 4 | |a Lumbar facet joint | |
| 650 | 4 | |a Lumbar epidural | |
| 650 | 4 | |a Sacroiliac joint injections | |
| 700 | 1 | |a Lee, Benjamin J. |4 aut | |
| 700 | 1 | |a Shi, Helen H. |4 aut | |
| 700 | 1 | |a Shakir, Hakeem J. |4 aut | |
| 700 | 1 | |a Cornett, Elyse M. |4 aut | |
| 700 | 1 | |a Kaye, Alan D. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pain and headache reports |d Springer US, 2001 |g 26(2022), 10 vom: 10. Sept., Seite 741-749 |w (DE-627)333033485 |w (DE-600)2055062-5 |w (DE-576)094530270 |x 1531-3433 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2022 |g number:10 |g day:10 |g month:09 |g pages:741-749 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11916-022-01082-2 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2022 |e 10 |b 10 |c 09 |h 741-749 | ||